eligibility_summary
Inclusion: Age ≥2, SRNS per KDIGO refractory to 12 mo of two drugs (≥1 CNI) or relapsed, or no remission after 3–6 mo on CNI, biopsy MCD or FSGS, adequate heart/renal/liver/lung function, negative pregnancy test+contraception. Exclusion: prior CAR/gene therapy, recent CNS disease, hereditary nephropathy, non-MCD/FSGS biopsy, RRT ≤3 mo, serious cardiac disease, recent transplant/GVHD, active HBV/HCV/HIV/syphilis/CMV, live vaccine ≤4 wk, malignancy, other trial ≤1 mo, PI discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06553898 tests anti-BCMA/CD70 CAR-T cells for multi-drug–resistant steroid-resistant nephrotic syndrome (MDR-SRNS). Intervention: autologous, gene‑modified cellular immunotherapy (CAR‑T). Mechanism: patient T cells are engineered to express CARs targeting BCMA and CD70, enabling antigen-specific cytotoxic depletion of pathogenic immune cells. BCMA targeting eliminates long‑lived plasma cells/plasmablasts to curb autoantibody production, CD70 targeting removes activated lymphocytes (B cells and subsets of T cells) involved in the CD70–CD27 co‑stimulatory pathway. Cells/pathways targeted: BCMA+ plasma cells, CD70+ activated B/T cells (and some APCs), thereby suppressing humoral autoimmunity implicated in SRNS and reducing immune-mediated podocyte injury. Design: Phase 1, single‑arm dose escalation/expansion (0.3–3×10^5/kg, up to 6×10^5/kg) to assess safety and efficacy.